← Back to Search

Senolytic

Dasatinib + Quercetin for Premature Aging in Mental Illness

Phase 2
Recruiting
Led By Eric Lenze, MD
Research Sponsored by Washington University School of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 10 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial will study if two drugs can slow aging in people with depression or schizophrenia.

Who is the study for?
This trial is for people aged 50+ with schizophrenia or 60+ with treatment-resistant major depression. Participants must have three aging-related conditions like hypertension, diabetes, or arthritis, and be on stable medication for their mental disorder. They can't join if they have dementia, recent severe illnesses (like heart attacks), uncontrolled health issues (high blood pressure/diabetes), certain drug interactions, or are at risk of harming themselves.
What is being tested?
The study tests a combination of dasatinib plus quercetin in older adults with depression or schizophrenia to see if it slows down aging. It's an open-label pilot study where everyone knows what treatment they're getting.
What are the potential side effects?
Possible side effects from dasatinib include fluid retention, bleeding problems, and immune system effects; quercetin may cause headaches and tingling in the arms/legs. The combination could potentially amplify these effects.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~10 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 10 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of participants who successfully completed and safely tolerated the intervention

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Dasatinib + quercetinExperimental Treatment1 Intervention
open label dasatinib plus quercetin combined as a drug therapy

Find a Location

Who is running the clinical trial?

Washington University School of MedicineLead Sponsor
1,991 Previous Clinical Trials
2,295,825 Total Patients Enrolled
UConn HealthOTHER
214 Previous Clinical Trials
60,591 Total Patients Enrolled
Eric Lenze, MDPrincipal InvestigatorWashington University School of Medicine, Department of Psychiatry
9 Previous Clinical Trials
3,307 Total Patients Enrolled

Media Library

Dasatinib + Quercetin (Senolytic) Clinical Trial Eligibility Overview. Trial Name: NCT05838560 — Phase 2
Premature Aging Research Study Groups: Dasatinib + quercetin
Premature Aging Clinical Trial 2023: Dasatinib + Quercetin Highlights & Side Effects. Trial Name: NCT05838560 — Phase 2
Dasatinib + Quercetin (Senolytic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05838560 — Phase 2
~9 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top